Navigation Links
Synthetic Biologics to Report Second Quarter 2013 Financial Results
Date:8/8/2013

ROCKVILLE, Md., Aug. 8, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today that it intends to release its financial results for the second quarter ended June 30, 2013 on Wednesday, August 14, 2013.

The Company will hold an investor conference call on Wednesday, August 14, 2013, at 4:00 pm EDT. During the call, Jeffrey Riley, Synthetic Biologics' Chief Executive Officer, will provide a brief update of the Company's multiple sclerosis program and its infectious disease pipeline, including its oral enzyme candidate for the prevention of C. difficile infections and monoclonal antibody candidates for the treatment of Pertussis and Acinetobacter infections. C. Evan Ballantyne, Synthetic Biologics' Chief Financial Officer, will review the Company's financial results for the second quarter ended June 30, 2013.

Interested parties should call 1-800-860-2442 (U.S. toll free), 1-866-605-3852 (Canada), or +1 412-858-4600 (International), fifteen minutes before the start of the call to register. Registered callers on the toll free line may ask to be placed in the queue for the Question & Answer Session. The call will also be webcast over the Internet at http://www.videonewswire.com/event.asp?id=95523. If you are unable to participate during the live conference call, the webcast will be available for replay at the same URL, http://www.videonewswire.com/event.asp?id=95523 for 30 days after the call.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology company focused on the development of biologics for the prevention and treatment of
'/>"/>

SOURCE Synthetic Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. "Sitting Ducks" No Longer: Advance Flu Warning Permits Creation of Replikins Custom Synthetic Flu Vaccine in Animals
2. Synthetic Biology: Emerging Global Markets
3. Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program
4. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
5. Startling results in synthetic chemistry presented in Nature Chemistry
6. Adeona Becomes Synthetic Biologics, Inc.
7. Synthetic Biologics to Present at ROTH Annual Growth Stock Conference
8. Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis
9. Synthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman
10. Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae Strains
11. Discovered Evolution of Genomic Sequences -- from Ocean Archaea to Brain Cancer -- Leads to New Synthetic Replikin Vaccines for Infectious Diseases and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015  Pfenex Inc. (NYSE ... financial results will be released on Thursday, August 13, ... Eastern Time, Pfenex management will host a conference call ... update.  A press release outlining the financial results and ... call. Please call 1-866-376-8058 (US) or 1-412-542-4131 ...
(Date:7/29/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ) ... optimized Erk inhibitor molecule for development, thus achieving ... new class of potential cancer therapies. ... for therapeutic intervention in cancer. Recently approved compounds ... B-Raf and Mek inhibitors. Erk inhibitors may be ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... Costello served ... levee system to protect the Orange County, Texas area from future storm surge ... design team in determining several potential levee alignment alternatives for providing protection, Costello also ...
(Date:7/28/2015)... July 29, 2015 A ... acquiring, rapidly developing and commercialising innovative medicines to ... Highly experienced management team; blue chip ...   Mereo BioPharma Group Ltd ("Mereo"), a recently-formed ... ( c. £76.5m), gross, from blue chip institutional investors ...
Breaking Biology Technology:Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3Preventing Storm Surge Flooding in Houston 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11
... 18 CV Therapeutics,Inc. (Nasdaq: CVTX ) ... (FDA) has approved new language for the product ... ability,of ranolazine to inhibit the late sodium current ... mechanism suggests that during ischemic,episodes excess sodium can ...
... (NYSE: DGX ), the nation,s leading provider ... its Board of,Directors declared a quarterly cash dividend ... payable on January 23, 2008, to shareholders of,record ... Quest Diagnostics is the leading provider of ...
... Ore., Dec. 18 Synthetech, Inc. (OTC,Bulletin ... Performance Improvement,Awards for their outstanding accomplishments in ... Silver Awards are presented by,the Synthetic Organic ... SOCMA,s EHS&S initiative. The awards are highly,regarded ...
Cached Biology Technology:FDA Approves New Mechanism of Action Labeling for Ranexa(R) 2Quest Diagnostics Declares Quarterly Cash Dividend 2Synthetech Earns National Recognition for Performance Improvement Program 2Synthetech Earns National Recognition for Performance Improvement Program 3
(Date:7/2/2015)... Fingerprint Cards has received an order for its ... distributor World Peace Industrial Group (WPI), part of WPG Holdings. ... . Deliveries are planned to take place during Q3 ... manufacturers in Asia . The order value ... of approximately 2,200 MSEK for 2015. Jörgen Lantto, ...
(Date:6/26/2015)... -- ATL Technology, LLC, a top provider of electromechanical contract ... solutions, headquartered in Springville, Utah , has ... corporation with locations in Santa Clara, ... ). This acquisition will incorporate MedConx,s manufacturing ... Technology,s existing facility in Costa Rica , ...
(Date:6/24/2015)... 24, 2015 The biologics safety testing market ... for the market include growth of the pharmaceutical and ... launches. Over the years, the number of drug approvals ... 2010, the FDA approved 225 drug applications and Health ... Europe accounted for 3,822 of the ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4
... of Community Health (MDCH) has unveiled the state,s ... significant recommendations developed from medical research conducted by ... Kennedy Shriver National Institute for Child Health and ... the Wayne State University School of Medicine. ...
... bottles from the drugstore the human body makes ... University have found a way to use naturally occurring ... Their method also serves as a highly sensitive hydrogen ... role in cellular health and disease. In a ...
... have known for some time that throwing off the ... fact, workers whose sleep-wake cycles are disrupted by night ... as diabetes, obesity and cancer. Researchers at the ... possible molecular link between circadian rhythm disturbances and an ...
Cached Biology News:State of Michigan adopts NIH's PRB progesterone therapy to combat infant mortality 2State of Michigan adopts NIH's PRB progesterone therapy to combat infant mortality 3Scientists discover molecular link between circadian clock disturbances and inflammatory diseases 2Scientists discover molecular link between circadian clock disturbances and inflammatory diseases 3
... Choice Microsphere/Microarray Stabilizer is a is a ... This product is an aqueous solution ... buffer (phosphate buffered saline), pH 6.6 - ... of 0.02% methylisothiazolone and 0.02% bromonitrodioxane as ...
... F1 antigen, Monoclonal Antibody, Unconjugated ... Use at an assay dependent dilution. ... dilution. WB: Use at an assay ... kDa. Not tested in other applications. ...
... formulated for mounting tissue specimens, cell smears, ... immunohistochemical methods for viewing by light microscopy. ... such as AEC, that are alcohol-soluble or ... when slides are cover-slipped forming a coating ...
... is formulated for covering tissue sections and cell preparations immunohistochemically ... products. , ... Application: Vision ... AEC that require an aqueous mounting medium, or those that ...
Biology Products: